Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson in critically injured patients with hemorrhagic shock
2018-003284-62Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hemorrhagic shock and Physical trauma comparing Rapiscan with Placebo (2 arms). Primary endpoint: Blood lactate level 2 hours post IMP administration. Status: unknown.
02
Drugs
regadenoson
03
Conditions
hemorrhagic shockPhysical trauma
Beyond the preview
Go deeper on 2018-003284-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003284-62.